Although HDAC inhibition accounts for the greater representation of epigenetic therapeutics (meaning lower acetyl levels tend to be associated with AD neuropathology), some studies have identified an opposite pattern of epigenetic modification. This evidence concerns the gene HDAC9 and Alzheimer disease.